Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hogg

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Cancers|July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint InhibitorsDeirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
JTO Clinical and Research Reports|April 17, 2025
Myasthenia Gravis in Patients Treated With Immune Checkpoint InhibitorsAbdulrahman Alghabban, Lucy Corke, Hans Katzberg, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaAxel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
Plos One|November 19, 2010
Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Linh T Nguyen, Pei Hua Yen, Jessica Nie, et al.
The Journal of Investigative Dermatology|November 19, 2010
A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindredsJulie M Lang, Michael Shennan, Jenny C-N Njauw, et al.
Cancer|February 16, 2019
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicitiesYada Kanjanapan, Daphne Day, Lisa Wang, et al.
Nature Genetics|June 18, 2002
Mutations in SUFU predispose to medulloblastomaMichael D Taylor, Ling Liu, Corey Raffel, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Cancers|July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint InhibitorsDeirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
JTO Clinical and Research Reports|April 17, 2025
Myasthenia Gravis in Patients Treated With Immune Checkpoint InhibitorsAbdulrahman Alghabban, Lucy Corke, Hans Katzberg, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaAxel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2018
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, Mathieu Lajoie, Dan Moldoveanu, et al.
Plos One|November 19, 2010
Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Linh T Nguyen, Pei Hua Yen, Jessica Nie, et al.
The Journal of Investigative Dermatology|November 19, 2010
A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindredsJulie M Lang, Michael Shennan, Jenny C-N Njauw, et al.
Cancer|February 16, 2019
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicitiesYada Kanjanapan, Daphne Day, Lisa Wang, et al.
Nature Genetics|June 18, 2002
Mutations in SUFU predispose to medulloblastomaMichael D Taylor, Ling Liu, Corey Raffel, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Pageof 8